Figure 1
From: Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway
Metformin attenuates olanzapine-induced metabolic disturbance and hepatic/hepatocyte lipid accumulation in mice and cells. (A) Plasma NEFA levels. (B) Plasma LDL-C levels. (C) Plasma TG levels. (D) Liver triglyceride levels. (E) Plasma ALT levels. (F) Plasma AST levels. (G) Body weight. (H) Liver weight/body weight ratio. (I) Triglyceride levels in HepG2 cells and AML12 cells. (J) H&E and ORO staining. (K) ORO absorbance at 520 nm in HepG2 cells and AML12 cells. Ctrl, control; OLZ, olanzapine; MET, metformin. Data represent the mean ± SEM. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. control; *p < 0.05, **p < 0.01, ***p < 0.001 vs. olanzapine; one-way ANOVA plus Tukey’s post-hoc test.
